Evidence map›Paper›PMID 35547173›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Therapeutic Applications of Magnetotactic Bacteria and Magnetosomes: A Review Emphasizing on the Cancer Treatment.

Sai Manogna Kotakadi, Deva Prasad Raju Borelli, John Sushma Nannepaga

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. CD4Sensors (Basel, Switzerland) · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Innovative Nanocarriers: Magnetosomes in the Fight against Cancer.Anti-cancer agents in medicinal chemistry · 2026
    Review
  6. Metabolic Gadolinium Labeling ofBiomaterials research · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.International journal of molecular sciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sai Manogna KotakadiDepartment of Biotechnology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, India.
Deva Prasad Raju BorelliDepartment of Physics, Sri Venkateswara University, Tirupati, India.
John Sushma NannepagaDepartment of Biotechnology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, India.
Sri Padmavati Mahila Visvavidyalayam · INSri Venkateswara University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetotactic bacteria (MTB) are aquatic microorganisms have the ability to biomineralize magnetosomes, which are membrane-enclosed magnetic nanoparticles. Magnetosomes are organized in a chain inside the MTB, allowing them to align with and traverse along the earth's magnetic field. Magnetosomes have several potential applications for targeted cancer therapy when isolated from the MTB, including magnetic hyperthermia, localized medication delivery, and tumour monitoring. Magnetosomes features and properties for various applications outperform manufactured magnetic nanoparticles in several ways. Similarly, the entire MTB can be regarded as prospective agents for cancer treatment, thanks to their flagella's ability to self-propel and the magnetosome chain's ability to guide them. MTBs are conceptualized as nanobiots that can be guided and manipulated by external magnetic fields and are driven to hypoxic areas, such as tumor sites, while retaining the therapeutic and imaging characteristics of isolated magnetosomes. Furthermore, unlike most bacteria now being studied in clinical trials for cancer treatment, MTB are not pathogenic but might be modified to deliver and express certain cytotoxic chemicals. This review will assess the current and prospects of this burgeoning research field and the major obstacles that must be overcome before MTB can be successfully used in clinical treatments.

Indexed as

biocompatiblecancer treatmentmagnetic fieldmagnetosomesmagnetotactic bacteriatherapeutic applications.

Identifiers

PMID35547173
PMCPMC9081342
OpenAlexW4224315377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.